Forest Laboratories announced that Fetzima (levomilnacipran extended-release) capsules are now available. Fetzima was approved in July 2013 for the treatment of major depressive disorder (MDD).

RELATED: Psychiatric Disorders Resource Center

Fetzima is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). The exact mechanism of the antidepressant action of levomilnacipran is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system through inhibition of reuptake at serotonin and norepinephrine transporters

Fetzima is available as 20mg capsules in 30-count bottles, and as 40mg, 80mg, 120mg capsules in 30- and 90-count bottles. The Fetzima Titration Pack  is supplied as two 20mg capsules and twenty-six 40mg capsules.

For more information call (800) 678-1605 or visit